Immunotherapy plus chemo for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced endometrial cancer (stage III or IV) that has not been treated with surgery yet.
- You are between 18 and 75 years old.
- You are in good physical condition (able to do your daily activities without trouble).
- You have not had immunotherapy (like Keytruda or Opdivo) before.
- You do not have an active autoimmune disease or serious infection.
- Your liver, kidney, and blood cell counts are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—an oral chemotherapy (topotecan) and an immunotherapy (toripalimab)—for advanced or recurrent endometrial cancer that has not responded to first-line treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of the immunotherapy drug tislelizumab (which helps your immune system fight cancer) with standard chemotherapy, given before surgery for advanced endometrial cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a new drug, cadonilimab (AK104), combined with chemotherapy for women with advanced or recurrent endometrial cancer. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a combination of immunotherapy (adebrelimab) with chemotherapy (carboplatin and paclitaxel), followed by adebrelimab with or without apatinib (a targeted therapy). It is for people with advanced or first-recurrent endometrial cancer who haven't had prior immunotherapy or certain targeted drugs.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
Hear when a new Endometrioid Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.